3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Pancreatic Neoplasms
2
Sarcoma
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Melanoma
1
Kidney Neoplasms
1
Colorectal Neoplasms
1
Breast Neoplasms
1
Interventions
Letrozole
25
Fulvestrant
25
Specimen Handling
19
ribociclib
16
Capecitabine
16
pembrolizumab
14
palbociclib
14
Paclitaxel
14
Trastuzumab
13
Carboplatin
13
exemestane
12
abemaciclib
12
Tamoxifen
12
Anastrozole
12
Magnetic Resonance Spectroscopy
11
trastuzumab deruxtecan
8
pertuzumab
8
Biopsy
8
Goserelin
7
inavolisib
6
giredestrant
6
Cyclophosphamide
6
130-nm albumin-bound paclitaxel
6
patritumab deruxtecan
5
eribulin
5
elacestrant
5
Taxes
5
Standard of Care
5
Radiotherapy
5
Gonadotropin-Releasing Hormone
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Breast Neoplasms
×
Genetic Counseling
×
30 days
×
Clear all
NCT05225428
2026-05-22
VERDI
Dana-Farber Cancer Institute
Phase NA
Recruiting
1,020 enrolled